Revvity stock edges lower as SuperFlex launch and Q2 earnings shape valuation debate

Revvity Inc. (US76155R1086) stock traded at $113.99 at the close on August 18, 2026, down 1.88% on the day as investors digested the company’s new SuperFlex prenatal screening system alongside recent second quarter 2026 earnings.

SuperFlex launch highlights growth ambitions

On August 19, 2026, Revvity announced the launch of its SuperFlex prenatal screening system, a compact CE-IVDR certified immunoassay instrument targeted at laboratories and clinics that need rapid, high-quality screening solutions for lower-volume workflows. The system supports testing for preeclampsia, a condition affecting between 2% and 8% of pregnancies globally, an area where demand is rising with higher maternal age and more prevalent chronic conditions such as diabetes. The Businesswire press release on Revvity SuperFlex describes the platform as designed to bring reliable prenatal screening closer to routine clinical practice in smaller settings.

By focusing SuperFlex on preeclampsia and related prenatal screening, Revvity is targeting a clinically important niche that may support incremental revenue from its diagnostics segment over time. The CE-IVDR certification positions the system for European markets that require compliance with the latest in-vitro diagnostic regulation, which could help broaden the company’s geographic reach for prenatal testing solutions.

Q2 2026 earnings and valuation context

Recent commentary on Revvity’s second quarter 2026 performance highlights that the company delivered steady earnings against a backdrop of strong share price momentum, with a 90 day share price return of 21.17% and a one-year total shareholder return of 29.88%. A Simply Wall St overview of Revvity notes that the SuperFlex launch comes just as investors assess the latest quarterly numbers, suggesting the product rollout forms part of a broader effort to sustain growth.

The same analysis frames Revvity’s valuation through a fair value estimate, citing a narrative where the shares trade at a modest discount to intrinsic value. One valuation model points to a fair value of $121.07 per share compared with a recent closing price of $116.17, implying the stock traded 4% below that fair value benchmark at the time of the assessment. An article on Revvity valuation after SuperFlex launch describes the shares as modestly undervalued rather than deeply discounted, tying that view to the company’s operating performance and product pipeline.

While full detail on the latest quarter’s revenue and earnings mix is not provided in the same-day commentary, the characterization of second quarter 2026 earnings as steady supports the view that Revvity delivered results consistent with recent trends. In that context, the double-digit share price gains over the last 90 days and near-30% total return over the past year indicate investors have rewarded the company for both financial delivery and strategic initiatives such as the SuperFlex launch.

Share performance and market metrics

From a market perspective, Revvity shares have advanced meaningfully over the last several months even after the modest 1.88% decline on August 18, 2026, which brought the closing price to $113.99. A MarketBeat Revvity stock overview notes that since a previous reference point, the stock has risen 17.7% to reach that level, underlining how the recent pullback comes after a strong run.

Market data also show Revvity’s market capitalization at $10.459 billion, based on a price-to-earnings ratio of 18.43 that places the stock in a mid-teens earnings multiple range. A Macrotrends market data table lists Revvity among U.S. companies with that market cap and valuation profile, situating it as a mid-cap healthcare and diagnostics player with room to grow if SuperFlex and other offerings deliver sustained revenue contributions.

These figures give investors several reference points for assessing Revvity’s valuation: a current share price of $113.99 as of August 18, 2026, a 17.7% rise from an earlier level highlighted in performance tracking, a 21.17% gain over the last 90 days, and a one-year total shareholder return close to 29.88%. Taken together, they show that the stock’s recent trajectory has been upward, supported by consistent earnings and an expanding diagnostics portfolio, even if short-term trading sessions bring occasional declines.

SuperFlex prenatal screening system in practice

The SuperFlex prenatal screening system is positioned as a compact immunoassay platform designed specifically for laboratories and clinics that handle lower testing volumes but still require sophisticated, reliable prenatal screening. According to the launch announcement, the instrument’s footprint and throughput aim to fit into resource-constrained settings, allowing a wider range of healthcare providers to offer advanced preeclampsia screening without investing in large-scale equipment. The Businesswire description of SuperFlex emphasizes its suitability for workflows where speed and reliability are critical but sample volumes are moderate.

Clinically, preeclampsia remains a leading concern in obstetric care, and the system’s focus on supporting tests for this condition reflects Revvity’s strategy to expand its footprint in women’s health diagnostics. With the condition affecting 2% to 8% of pregnancies and incidence rising, offering more accessible screening options could help reduce morbidity by enabling earlier risk stratification and intervention. For investors, that translates into a clearer link between the company’s product innovation and potential demand drivers in healthcare systems facing demographic and chronic disease shifts.

Stock outlook anchored in products and earnings

Looking ahead, the combination of SuperFlex’s introduction and solid second quarter 2026 earnings provides a basis for continued interest in Revvity stock among investors who focus on diagnostics and life sciences. The modest valuation discount implied by fair value estimates, combined with a price-to-earnings ratio of 18.43 and a market cap of $10.459 billion as shown in recent data, suggests the market is pricing Revvity as a company with stable earnings and growth potential rather than as a high-growth, high-multiple name.

As of the most recent completed trading session on August 18, 2026, Revvity stock closed at $113.99 on the NYSE, reflecting the latest balance between enthusiasm for initiatives like SuperFlex and profit-taking after a strong multi-month rally.

Read more

Further details on Revvity’s business, including its broader diagnostics and life sciences portfolio, can be found on the company’s website. Investors may also review the latest quarterly presentations and filings for a deeper view of segment performance, margins, and capital allocation priorities.

Revvity’s prenatal screening offering

Within Revvity’s product ecosystem, the SuperFlex prenatal screening system stands out as a representative offering that underscores the company’s emphasis on accessible precision diagnostics. By enabling preeclampsia testing in lower-volume labs, SuperFlex aligns with healthcare trends that prioritize early detection and risk management, complementing other maternal-fetal health solutions that the company provides through its diagnostics platforms.

Revvity stock and recent price level

Revvity stock, listed on the NYSE under the ticker RVTY, closed at $113.99 on August 18, 2026, in U.S. dollar trading, marking a 1.88% decline for that session after a period of strong gains over the previous 90 days and the past year.

Fact box

Company: Revvity Inc.
ISIN: US76155R1086
Ticker: RVTY
Exchange: NYSE
Price (as of August 18, 2026, 3:59 p.m. ET): $113.99 USD
Market cap: $10.459 billion (as of August 18, 2026)
Sector / Industry: Health care equipment and services / Diagnostics